Neuro-Biotech Corp. Updates on Due Diligence

BASEL, Switzerland, Feb. 28 /PRNewswire/ - Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES) is pleased to provide its shareholders updates about the due diligence process and the conditions of the unsolicited offer. As of Friday February 25, all the conditions required by the parties in order to complete their due diligence have been met:

• AURIC Pharma Science has provided financial statements proving its ability to complete the purchase.
• AURIC Pharma Science has provided detailed distribution network of its products and services.
• Neuro-Biotech Corp.has provided patent information on all its exclusive products and services.
• Neuro-Biotech Corp. has provided all previous and effected purchase orders, as well as future pending orders.

Neuro-Biotech management has decided to publish some of this information directly on its website in order for the shareholder to access it easily.

Management would also like to announce that management is expecting to complete it's diligence process by the end of the day on March 4, 2011.

For more information on Neuro-Biotech Corp or to contact a company representative, please visit: www.neuro-biotechcorp.com

FORWARD LOOKING STATEMENTS

This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

SOURCE Neuro-Biotech Corp.

Copyright . 28 PR Newswire